t1dm.org

My lecture at the DISCT (Diabetes, Insulin and Stem Cell Therapy) Masterclass, hosted by CliMed Research Solutions on the topic of 'Regenerative Medicine: A Newer Approach For Autoimmune Diabetes'. My special thanks to Dr Ajit Singh for this opportunity!  The following video is a deep dive into this approach: For more publications and discussions on T1DM, visit: https://www.t1dm.org   For queries or feedback, email info@t1dm.org  or leave a comment below.

Background and objective : Type 1 diabetes mellitus is a complex disease defined by the loss of pancreatic cells, which leads to complete insulin insufficiency. The Diabetes Control and Problems Trial defines the aims of Type 1 diabetes therapy as achieving adequate glycaemic control and preventing and avoiding recurrent bouts of hypoglycaemia. Despite ongoing efforts to improve insulin therapy regimens, the actual hormone substitute therapy treats just the symptoms of the disease, with no influence on disease pathology or etiopathogenesis. In recent decades, there has been a lot of interest in preventative techniques in high-risk patients, based on the theory that if a therapeutic intervention is adopted early in the disease, it can help maintain endogenous cell function by protecting the remaining cell reservoir from autoimmune attack. Authors : Prajakta Kashalikar , Shivani Desai , Avinash Sanap, Madhura Shekatkar, Ramesh Bhonde Journal : Recent Advances in Inflammation & Allerg

Abstract : Several cellular and molecular therapies such as stem cell therapy, cell replacement therapy, gene modification therapy and tolerance induction therapy have been researched to procure a permanent cure for Type 1 Diabetes. However, due to the induction of undesirable side effects, their clinical utility is questionable. These anti-diabetic therapies can be modified with nanotechnological tools for reducing adverse effects by selectively targeting genes and/or receptors involved directly or indirectly in diabetes pathogenesis such as the glucagon-like peptide 1 receptor, epidermal growth factor receptor, human leukocyte antigen [HLA] gene, miRNA gene and hepatocyte growth factor [HGF] gene. This paper will review the utilities of nanotechnology in stem cell therapy, cell replacement therapy, beta-cell proliferation strategies, immune tolerance induction strategies and gene therapy for type 1 diabetes management. Journal : Pharmaceutical Nanotechnology Keywords : Autoimmunity

Abstract : Type 1 diabetes mellitus (T1DM), an autoimmune disease, involves the destruction of pancreatic β cells. β cells maintain glucose homeostasis by identifying blood glucose and accordingly releasing insulin in order to maintain normal physiologic glucose levels. Human umbilical cord blood (hUCB) cells posture a lesser risk of viral contamination as there is low placental transmission during prenatal life. Additionally, they have advantages such as non-invasive harvest procedure gynaecological waste, low immunogenicity, easy expansion in-vitro, and easy ethical access as compared to deriving stem cells from other sources. According to the published preclinical data infusion of autologous cord blood cells is considered to be safe as they are non-antigenic. Depending on the degree of differentiation, the ability to regenerate themselves, and the origin of many stem cell types can be differentiated. The application of stem cells (SCs) embraces the great potential for the management

Abstract : Type 1 diabetes mellitus (T1DM), an autoimmune disease, involves destruction of pancreatic β cells. β cells maintains glucose homeostasis by identifying blood glucose and accordingly releasing insulin in order to maintain normal physiologic glucose levels. Human umbilical cord blood (hUCB) cells posture a lesser risk of viral contamination as there is low placental transmission during prenatal life. Additionally, they have advantages such as non-invasive harvest procedure gynecological waste, low immunogenicity, easy expansion in-vitro, and easy ethical access as compared to deriving stem cells from other sources. According to the published preclinical data infusion of autologous cord blood cells is considered to be safe as they are non-antigenic. Depending on the degree of differentiation, the ability to regenerate themselves, and the origin of many stem cell types can be differentiated. The application of stem cells (SCs) embraces great potential for the management of T1DM

I recently delivered a lecture at Masters Certificate Course in Diabetic Pharmacotherapy (MCCDP), hosted by CliMed Research Solutions on the topic of 'Pathophysiology and Pharmacology of Type 1 Diabetes Mellitus'. Special thanks to Dr Ajit Singh for this opportunity!  Understanding the disease's pathophysiology can help in managing it better. The following video is a deep dive into this approach.  For more videos and discussions on T1DM, visit: https://www.t1dm.org For queries or feedback, email info@t1dm.org or simply leave a comment below.

Balanced Th1 and Th2 cytokines are significantly associated to maintain the immunological ecosystem in human physiology. Any imbalance can lead to either autoimmune diseases or immunodeficient diseases. This editorial highlights the immunological mechanism involved in type 1 diabetes (T1DM). Journal : Current Diabetes Reviews Keywords : Cytokines; T1D; T2D; anti-inflammatory; immunological processes; proinflammatory Read Full Editorial

The history of insulin is a 100 years story. This marvel has become a blessing for Type 1 Diabetic Mellitus (T1DM) patients. This video describes the complete journey of insulin from even before its scientific discovery.  Related article: A Century-Long Journey Of Type 1 Diabetes Management: From Insulin To…?? For more videos and discussions on T1DM, visit: https://www.t1dm.org For queries or feedback, email info@t1dm.org or simply leave a comment below.

Insulin is the only available treatment for Type 1 Diabetes Mellitus (T1DM) for over a century now. Globally, scientists are working on different avenues to find a permanent cure for T1DM. Clinical trials are under process, but with little success so far. So where are we today? A short video: Related article:  A Century-Long Journey Of Type 1 Diabetes Management: From Insulin To…??   For more publications and discussions on T1DM, visit: https://www.t1dm.org    For queries or feedback, email info@t1dm.org  or simply leave a comment below.

The history of type 1 diabetes mellitus (T1DM) is a longstanding story and during this 'Diabetes Month', we have designed this platform to discuss various aspects of this disease. This video is an introduction to T1DM on the occasion of Diabetes Day 2021. For more videos and publications on T1DM, visit www.t1dm.org . For queries or feedback, email info@t1dm.org  or simply leave a comment below.

Survey Objective : Type 1 diabetes mellitus (T1DM) is growing in incidence over a few years. The objective of this short survey is to report the viewpoint of the general population about their belief if type 1 diabetes mellitus (T1DM) can be prevented. This will further motivate the researchers to accelerate their research to develop vaccines for the prevention and reversal of T1DM. Methods : A survey was put up on LinkedIn asking a single question “Type 1 diabetes is preventable: Agree or disagree”. The poll was kept open for a period of two weeks and 220 votes were obtained from people belonging to the healthcare sector (n=168) as well as other professions (n=52). Results : Out of 220 votes, 64% of people agree that T1DM is preventable and the remaining 36% disagree. Conclusions : Results indicate that majority of people think that T1DM is preventable. Though there is no preventive vaccine at present, there is a hope to formulate such a vaccine that can prevent this autoimmune diabet

Coronavirus disease 2019 (COVID-19) has stimulated health concerns globally, especially in diabetes where it has been accompanied by severe outcomes. Type 2 diabetes mellitus (T2DM) is a chief worry; though, there are a considerable population of patients with type 1 diabetes mellitus (T1DM) also, that too with incomparable concerns during the current COVID-19 pandemic. Some children experience significant complications related to this disease and paediatric deaths have also been reported. This article describes some key points related to the complications and management of concomitant T1DM and COVID-19. Read Full Article Source : Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research Blog Keywords : Blood Glucose, Diabetes, COVID-19, Insulin     

Can you answer this question mark in the title? What is the next product coming in the market for reversing or managing type 1 diabetes?  The history of type 1 diabetes (T1DM) is a longstanding story. However, its management became possible only after the discovery of insulin by Frederick Banting and Charles Best in 1921. With this, scientists started developing hopes to cure this disease. Unfortunately, this goal is yet to be accomplished. This article gives a tour of the various advancements in managing T1DM and how still there is no cure for this perilous disease. Insulin: The First Weapon to Fight T1DM The discovery of insulin was not by chance, it was a very well-thought science. The cascade goes as follows: 1889 : Joseph von Mering and Oskar Minkowski observed that removing the pancreas from dogs developed diabetes in them, followed by their death shortly. 1910 : Sir Edward Albert Sharpey-Schafer projected that the lack of a specific chemical produced by the pancreas is responsib

Abstract : The incidence of type 1 diabetes mellitus (T1DM), an autoimmune disorder, has ascended considerably with around 98,200 and 15,900 incidents in children below 15 years of age, globally and in India, respectively. This is typically due to environmental changes leading to genetic modifications. Also, T1DM encompasses the presence of autoantigens and many other etiologies which can be targeted by proper immunization. In this paper, we consciously discuss and collate various candidate triggers of islet autoimmunity and other factors expected to promote the progression of T1DM. This paper bridges all the mechanisms caused by these factors and links them with each other. We have also highlighted the novel coronavirus as a trigger for T1DM. Finally, we suggest that an amalgamated model of polyvaccine can batter the condition by inducing protection against various triggers of T1DM. Journal : Clinical and Experimental Vaccine Research  Keywords : Type 1 diabetes mellitus; Viruses; Cor

Abstract : Type 1 diabetes mellitus (T1DM) is an autoimmune disease that leads to the destruction of pancreatic β-cells, thereby causing insufficient insulin production. Globally, around 98, 200 children and adolescents below 15 years of age and almost 128,900 subjects below 20 years of age develop T1DM annually, along with severe complications deteriorating their quality of life. In India alone, around 15,900 incident cases below 15 years have been reported annually. Hence, its prevention and reversal are significant. Unlike other chronic diseases, T1DM involves the presence of various autoantigens which can be targeted by proper immunisation. The development of reliable immuno-regulatory surrogate markers would be of great benefit. Vaccines can be one of such strategies in the journey to prevent T1DM. It would not only benefit greatly to reduce the sufferings caused due to diabetic complications but could also help to reverse T1DM, by modulating the immunological autoantigenic reacti

Abstract : Diabetes mellitus is a common metabolic disorder affecting a wide range of populations worldwide. There are many types of diabetes mellitus, one of which is type 1 diabetes mellitus (T1DM). It is an autoimmune disorder caused in about 97,700 children in India and 490,000 children globally. Many etiological factors contribute to this disease. This review article is a collage of etiological factors causing T1DM. A better understanding of aetiology is significant for the prevention and management of the disease. Journal : Pharmaceutical Resonance  Keywords : Type 1 Diabetes Mellitus; Etiology; Autoantibodies; Extracellular matrix; Coxsackievirus B virus Read Full Review Paper

Abstract : Type 1 diabetes mellitus (T1DM), an autoimmune disorder, is becoming widespread with approximately 97,700 children in India and 490,000 children worldwide affected. There are various etiological factors contributing to the expansion of its incidence in different geographical locations. Hence, the articles published in reputed journals were studies and data was collected for analyzing the aetiology and prevention of T1DM. It has been observed that hybrid insulin peptides act as key antigens for the autoreactive T cells and causes loss of self-tolerance in humans. The association of coxsackievirus B has been observed with the onset of T1DM. Accurate identification of the trigger can lead to the development of appropriate preventive measures. It can become a base for advanced studies to prevent T1DM in humans. This review will highlight the causes and some preventive actions which can be considered to eliminate T1DM. Journal : Current Diabetes Reviews Keywords : Type 1 diabete

Scientists have identified the possible trigger for type 1 diabetes mellitus (T1DM). The T cells of the immune system do not recognise self-antigens, i.e., the body’s own cells. Therefore, they are protected from the attack of the immune system. In T1DM and other autoimmune disorders, this protective system gets disrupted 1 . Dr Delong and his colleagues carried out an experiment to study the trigger in T1DM. They isolated T cells from a T1DM mouse model and determined the trigger that is recognised as a foreign body in the insulin-producing β-cells. They recognised a modified version of insulin which acted as an antigen. They also observed that the immune T cells from pancreatic islets of two organ donors with T1DM recognised hybrid insulin peptides (HIPs). This study concluded that these HIPs may have a significant role as a trigger to the immune system and hence attack the body’s insulin-producing pancreatic β-cells, thus causing T1DM 1 . Antibodies from the blood of T1DM patients

T1DM is allied with the selective destruction of insulin-producing β-cells in the pancreas. The commencement of clinical disease signifies the end stage of β-cell destruction which leads to T1DM. There is marked heterogeneity of the pancreatic lesions, which makes it difficult to follow the pathogenesis of selective β-cell destruction within the islet in T1DM 1 .

Diabetes mellitus (DM), a metabolic disorder, is mainly of two types. Type 1 Diabetes Mellitus (T1DM), insulin dependent DM, is an autoimmune reaction to proteins of the islet cells of the pancreas. There is a lack of insulin secretion by β- cells of the pancreas. Type 2 Diabetes Mellitus (T2DM), non-insulin dependent DM, is a combination of genetic factors related to impaired insulin secretion, insulin resistance and environmental factors such as obesity, overeating, lack of exercise, stress, ageing. There is a decreased sensitivity of target tissues to insulin 1 .